[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1990

A Randomized Clinical Trial of Prophylactic OKT3 Monoclonal Antibody in Liver Allograft Recipients

Author Affiliations

From the Transplantation Unit, Massachusetts General Hospital, and the Department of Surgery, Harvard Medical School, Boston (Drs Cosimi and Delmonico); Transplantation Service and Department of Surgery, New England Deaconess Hospital, Boston (Drs Jenkins and Monaco); and the Transplantation Service and Departments of Surgery and Medicine, Tufts–New England Medical Center, Boston (Drs Rohrer and Hoffman).

Arch Surg. 1990;125(6):781-785. doi:10.1001/archsurg.1990.01410180107017
Abstract

• Seventy-nine hepatic allograft recipients were randomized to receive either conventional immunosuppression, including cyclosporine, azathioprine, and steroids (41 patients), or investigational therapy in which OKT3 replaced cyclosporine during the first postoperative week (38 patients). Early rejection occurred in 29 patients (71 %) in the conventional group and 15 patients (39%) in the OKT3 group. Posttransplantation renal dysfunction occurred in 12 patients (29%) in the conventional group and 6 patients (16%) in the OKT3 group. Mean initial hospital stay was 34.1 ±18.8 days in the conventional group compared with 29.1 ±16.8 days in the OKT3 group. Cumulative patient survival (mean follow-up, 17.8±7.1 months) was 73.2% (30/41) for the conventional group and 84.2% (32/38) for the OKT3 group. Prophylactic OKT3 is indicated especially for liver allograft recipients with other complicating conditions that make management of early rejection unusually difficult.

(Arch Surg. 1990;125:781-785)

×